LENZ Therapeutics Grants Arrotex Exclusive Rights to VIZZ in Australia, New Zealand
The licensing agreement extends the ophthalmology treatment's geographic footprint as LENZ pursues regional partnerships for commercial expansion.
LENZ Therapeutics has granted Arrotex Pharmaceuticals exclusive rights to commercialize VIZZ in Australia and New Zealand under a new licensing agreement, marking the latest geographic expansion for the ophthalmology treatment.
The arrangement grants Arrotex responsibility for marketing, distribution, and sales operations across both markets. Financial terms of the agreement were not disclosed. LENZ retains rights to VIZZ in other territories and maintains its existing commercial operations elsewhere.
Arrotex Pharmaceuticals brings established distribution infrastructure and regulatory expertise in the Oceania region to the partnership. The company's existing market presence positions it to handle regulatory approvals and manage the product launch timeline across both territories.
LENZ Therapeutics has pursued a regional partnership strategy to expand VIZZ's geographic reach while maintaining focus on core markets. The Australia and New Zealand agreement reflects broader industry trends in which specialty pharmaceutical companies license regional rights to local or regional operators with established healthcare relationships and regulatory pathways.
The licensing model allows LENZ to monetize intellectual property across new geographies without requiring direct infrastructure investment in these markets. For Arrotex, the exclusive rights provide a branded treatment addition to its existing ophthalmology portfolio.
The commercial timeline for VIZZ's availability in Australia and New Zealand will depend on completion of regulatory approval processes in each country. Both markets represent mature healthcare systems with established pharmaceutical approval frameworks, though specific timelines for market entry were not provided.